Autolus Therapeutics (NASDAQ:AUTL) Shares Down 4.6% - What's Next?

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) shares dropped 4.6% during mid-day trading on Wednesday . The company traded as low as $4.07 and last traded at $4.14. Approximately 194,190 shares traded hands during trading, a decline of 86% from the average daily volume of 1,339,275 shares. The stock had previously closed at $4.34.

Autolus Therapeutics Stock Down 4.6 %

The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09. The company has a 50-day simple moving average of $4.04 and a 200 day simple moving average of $4.07. The company has a market cap of $1.10 billion, a P/E ratio of -3.62 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.03). On average, equities analysts anticipate that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Avoro Capital Advisors LLC purchased a new stake in shares of Autolus Therapeutics in the first quarter valued at approximately $78,765,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Autolus Therapeutics by 82.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company's stock worth $35,020,000 after buying an additional 2,487,778 shares during the period. Great Point Partners LLC grew its position in shares of Autolus Therapeutics by 195.0% during the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company's stock worth $11,977,000 after buying an additional 2,275,000 shares in the last quarter. Affinity Asset Advisors LLC grew its position in shares of Autolus Therapeutics by 117.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,375,000 shares of the company's stock worth $21,532,000 after buying an additional 1,824,592 shares in the last quarter. Finally, Armistice Capital LLC increased its stake in shares of Autolus Therapeutics by 33.8% during the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company's stock valued at $21,750,000 after buying an additional 1,578,000 shares during the period. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.